Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 242

1.

Outcome definitions and predictors in depression.

Tedlow J, Fava M, Uebelacker L, Nierenberg AA, Alpert JE, Rosenbaum J.

Psychother Psychosom. 1998 Jul-Oct;67(4-5):266-70.

PMID:
9693355
2.

Fluoxetine treatment of depressed patients with comorbid anxiety disorders.

Sonawalla SB, Farabaugh A, Johnson MW, Morray M, Delgado ML, Pingol MG, Rosenbaum JF, Fava M.

J Psychopharmacol. 2002 Sep;16(3):215-9.

PMID:
12236627
3.

Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor.

Lenox-Smith AJ, Jiang Q.

Int Clin Psychopharmacol. 2008 May;23(3):113-9. doi: 10.1097/YIC.0b013e3282f424c2.

PMID:
18408525
4.

Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder.

Trivedi MH, Pigotti TA, Perera P, Dillingham KE, Carfagno ML, Pitts CD.

J Clin Psychiatry. 2004 Oct;65(10):1356-64.

PMID:
15491239
5.

The relationship between early changes in the HAMD-17 anxiety/somatization factor items and treatment outcome among depressed outpatients.

Farabaugh A, Mischoulon D, Fava M, Wu SL, Mascarini A, Tossani E, Alpert JE.

Int Clin Psychopharmacol. 2005 Mar;20(2):87-91.

PMID:
15729083
6.

Fluoxetine versus placebo in posttraumatic stress disorder.

Martenyi F, Brown EB, Zhang H, Prakash A, Koke SC.

J Clin Psychiatry. 2002 Mar;63(3):199-206.

PMID:
11926718
7.

Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression.

Fava M, Rosenbaum JF, Hoog SL, Tepner RG, Kopp JB, Nilsson ME.

J Affect Disord. 2000 Aug;59(2):119-26.

PMID:
10837880
8.

Sensitivity of the six-item Hamilton Depression Rating Scale.

O'Sullivan RL, Fava M, Agustin C, Baer L, Rosenbaum JF.

Acta Psychiatr Scand. 1997 May;95(5):379-84.

PMID:
9197901
9.

Efficacy of fluvoxamine in the treatment of major depression with comorbid anxiety disorders.

Sonawalla SB, Spillmann MK, Kolsky AR, Alpert JE, Nierenberg AA, Rosenbaum JF, Fava M.

J Clin Psychiatry. 1999 Sep;60(9):580-3.

PMID:
10520975
10.
11.
12.

Sociodemographic predictors of response to antidepressant treatment.

Spillmann M, Borus JS, Davidson KG, Worthington JJ 3rd, Tedlow JR, Fava M.

Int J Psychiatry Med. 1997;27(2):129-36.

PMID:
9565719
13.

Sertraline versus fluoxetine in the treatment of major depression: a combined analysis of five double-blind comparator studies.

Feiger AD, Flament MF, Boyer P, Gillespie JA.

Int Clin Psychopharmacol. 2003 Jul;18(4):203-10.

PMID:
12817154
14.

Should anxiety and insomnia influence antidepressant selection: a randomized comparison of fluoxetine and imipramine.

Simon GE, Heiligenstein JH, Grothaus L, Katon W, Revicki D.

J Clin Psychiatry. 1998 Feb;59(2):49-55.

PMID:
9501885
15.

Does early improvement triggered by antidepressants predict response/remission? Analysis of data from a naturalistic study on a large sample of inpatients with major depression.

Henkel V, Seemüller F, Obermeier M, Adli M, Bauer M, Mundt C, Brieger P, Laux G, Bender W, Heuser I, Zeiler J, Gaebel W, Mayr A, Möller HJ, Riedel M.

J Affect Disord. 2009 Jun;115(3):439-49. doi: 10.1016/j.jad.2008.10.011. Epub 2008 Nov 22.

PMID:
19027961
16.
17.

The effect of duloxetine on painful physical symptoms in depressed patients: do improvements in these symptoms result in higher remission rates?

Fava M, Mallinckrodt CH, Detke MJ, Watkin JG, Wohlreich MM.

J Clin Psychiatry. 2004 Apr;65(4):521-30.

PMID:
15119915
18.

Major depressive subtypes and treatment response.

Fava M, Uebelacker LA, Alpert JE, Nierenberg AA, Pava JA, Rosenbaum JF.

Biol Psychiatry. 1997 Oct 1;42(7):568-76.

PMID:
9376453
19.

Nefazodone in the treatment of elderly patients with depressive disorders: a prospective, observational study.

Saiz-Ruiz J, Ibañez A, Díaz-Marsá M, Arias F, Carrasco JL, Huertas D, Martín-Carrasco M, Moreno I, Rico-Villademoros F.

CNS Drugs. 2002;16(9):635-43.

PMID:
12153334
20.

A double-blind, multicenter, parallel-group study of paroxetine, desipramine, or placebo in breast cancer patients (stages I, II, III, and IV) with major depression.

Musselman DL, Somerset WI, Guo Y, Manatunga AK, Porter M, Penna S, Lewison B, Goodkin R, Lawson K, Lawson D, Evans DL, Nemeroff CB.

J Clin Psychiatry. 2006 Feb;67(2):288-96.

PMID:
16566626
Items per page

Supplemental Content

Write to the Help Desk